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A B S T R A C T
Background
Recurrent apnea is common in preterm infants, particularly at very early gestational ages. These episodes of loss of effective breathing
can lead to hypoxemia and bradycardia that may be severe enough to require resuscitation including use of positive pressure ventilation.
Methylxanthines (such as caffeine or theophylline) have been used to stimulate breathing and prevent apnea and its consequences.
Objectives
To determine the effects of methylxanthine treatment on the incidence of apnea and the use of intermittent positive pressure ventilation
(IPPV), and other clinically important effects in preterm infants with recurrent apnea.
Search strategy
Searches were made of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 4, 2007), the
Oxford Database of Perinatal Trials, MEDLINE (1966 to January 2008), EMBASE (1982 - January 2008), previous reviews including
cross references, abstracts, conferences and symposia proceedings, expert informants, journal hand searching mainly in the English
language.
Selection criteria
All trials utilizing random or quasi-random patient allocation in which methylxanthine (theophylline or caffeine) was compared with
placebo or no treatment for apnea in preterm infants were included.
Data collection and analysis
Methodological quality was assessed independently by the two review authors. Data were extracted independently by the two review
authors. Treatment effects were expressed as relative risk (RR) and risk difference (RD) and their 95% confidence intervals, using a
fixed effect model. For significant results, the inverse of the risk difference (1/RD) was used to calculate the number needed to treat
(NNT).
Main results
The results of five trials that enrolled a total of 192 preterm infants with apnea indicate that methylxanthine therapy leads to a reduction
in apnea and use of IPPV in the first two to seven days. There are insufficient data to adequately evaluate side effects and no data to
examine effects within different gestational age groups. There are no data in the included studies that examine long-term effects.
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Authors’ conclusions
Methylxanthines are effective in reducing the number of apneic attacks and the use of mechanical ventilation in the two to seven days
after starting treatment. In view of its lower toxicity, caffeine would be the preferred drug. The effects of methylxanthines on long-term
outcomes will be addressed in data from the trial awaiting assessment (CAP Trial 2006).
P L A I N L A N G U A G E S U M M A R Y
Methylxanthine treatment for apnea in preterm infants
There is some evidence that methylxanthines are effective in the short-term for reducing apnea in premature babies. Apnea is a pause
in breathing of greater than 20 seconds. It may occur repeatedly in preterm babies (born before 34 weeks gestation). Methylxanthines
(such as theophylline and caffeine) are drugs that are believed to stimulate breathing efforts and have been used to reduce apnea. Adverse
effects of feeding intolerance and a rapid heart rate have been found with theophylline. The review of trials found methylxanthines help
reduce the number of apnea attacks in the short term. The trials included in this review now have not published longer term outcomes,
although the general use for a number of indications has been evaluated and outcomes are better in the methylxanthine group. This
trial is awaiting assessment.
B A C K G R O U N D
Infant apnea has been defined as a pause in breathing of greater
than 20 seconds or one of less than 20 seconds and associated with
cyanosis, marked pallor, hypotonia or bradycardia (AAP 2003).
Recurrent episodes of apnea are common in preterm infants and
the incidence and severity increases at lower gestational ages (re-
viewed byHenderson-Smart 2004). Although recurrent apnea can
occur spontaneously and be attributed to prematurity alone, it can
also be provoked or made more severe if there is some additional
insult such as infection, hypoxemia or intracranial pathology.
If prolonged, apnea can lead to hypoxemia and reflex bradycardia
which may require active resuscitative efforts to reverse. There
are clinical concerns that these episodes might be harmful to the
developing brain or cause dysfunction of the gut or other organs.
Frequent episodes may be accompanied by respiratory failure of
sufficient severity to lead to intubation and the use of intermittent
positive pressure ventilation (IPPV).
Methylxanthines are thought to stimulate breathing efforts and
have been used in clinical practice to reduce apnea since the 1970’s
(reviewed by Samuels 1992; Henderson-Smart 2004; Comer
2001). Theophylline and caffeine are two forms that have been
used. The mechanism of their action is not certain. Possibilities
include increased chemoreceptor responsiveness (based on a lower
threshold for breathing responses to CO2), enhanced respiratory
muscle performance and generalized central nervous system exci-
tation.
Adverse effects such as feed intolerance and tachycardia have been
reported in observational studies, particularly with theophylline
therapy. There are potential adverse effects of increased central
nervous system stimulation on long term development of the ner-
vous system, although this has not been suggested from cohort
studies. The increased metabolic rate induced by methylxanthines
could increase the rate of blood oxygen desaturation during ap-
nea, even if the rate of events were reduced. A metabolic load, if
sustained, could affect growth. Issues of neonatal morbidity have
been reviewed (Blanchard 1992; Martin 1998; Schmidt 1999).
This review updates the existing review of ’Methylxanthine for
apnea in preterm infants’ which was published in the Cochrane
Library, Issue 4, 2004 (Henderson-Smart 2004a).
O B J E C T I V E S
To determine the effects of methylxanthine treatment on the inci-
dence of apnea and the use of intermittent positive pressure ven-
tilation (IPPV) and other clinically important effects in preterm
infants with recurrent apnea.
Prespecified subgroup analyses:
1. Effects of different methylxanthines (theophylline, caffeine)
2. Effects of different doses of methylxanthine
3. Effects at different gestational ages or birth weights
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M E T H O D S
Criteria for considering studies for this review
Types of studies
All trials utilizing random or quasi-random patient allocation were
included.
Types of participants
Preterm infants with recurrent apnea. There must have been an
effort to exclude specific causes of apnea.
Types of interventions
Anymethylxanthine (aminophylline, theophylline, caffeine) com-
pared with placebo or no treatment for recurrent apnea.
Types of outcome measures
Measures of the severity of apnea as well as the response to treat-
ment must have been consistent with an evaluation of ’clinical
apnea’, as defined by the American Academy of Pediatrics (AAP
2003, see Background).
Primary
1. Failed treatment (less than 50% reduction in apnea, or use
of IPPV, or death during study)
2. Use of IPPV
3. Death before hospital discharge
Secondary
1. Acute drug side effects (tachycardia or feed intolerance
leading to omission of treatment)
2. Neonatal morbidity such as - patent ductus arteriosus
requiring treatment, intracranial hemorrhage, necrotizing
enterocolitis
3. Duration of IPPV
4. Duration of oxygen therapy
5. Chronic lung disease indicated by respiratory support
(oxygen &/or positive airway pressure) still given at 36 weeks
postmenstrual age
6. Longer term outcomes, such as growth and
neurodevelopmental outcome
Search methods for identification of studies
Searches were made of the Cochrane Central Register of Con-
trolled Trials (CENTRAL, The Cochrane Library, Issue 4, 2007),
the Oxford Database of Perinatal Trials, MEDLINE (1966 to Jan-
uary 2008), EMBASE (1982 to January 2008), previous reviews
including cross references, abstracts, conferences and symposia
proceedings, expert informants, journal hand searching mainly in
the English language. Expert informant’s search in the Japanese
language was made by Pr of. Y. Ogawa in 1996. Searches used the
text terms ’apnea or apnea’, ’theophylline’, ’aminophylline’ or ’caf-
feine’; and Mesh term ’infant;premature’. All titles and abstracts
were reviewed to select random or quasi randomised trials. The
full papers were reviewed when only the title and the abstract did
not make eligibility clear.
Data collection and analysis
Trials were assessed for method of randomizations, blinding of
intervention, blinding of outcome assessment and completeness of
follow up. The methodological quality of each trial was reviewed
by the second author blinded to trial authors and institution(s).
Each author extracted data separately. Then data were compared
and differences resolved. Additional information was provided by
Gupta (Gupta 1981) on the use of IPPV.
Results were meta-analyzed using a fixed effect model and treat-
ment effects were expressed as relative risk (RR) and risk difference
(RD) and their 95% confidence intervals. For significant results,
we used the inverse of the risk difference (1/RD) to calculate the
number needed to treat (NNT). If there was significant hetero-
geneity based on I2 statistic that is unresolved by subgroup analy-
ses, the random effects RR was also reported.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
The five included trials (Sims 1985; Murat 1981; Peliowski 1990;
Gupta 1981; Erenberg 2000) studied a total of 192 infants. Details
of these studies are included in the table of included studies. No
studies were excluded.
One trial reported on the use of oral theophylline (Gupta
1981) and two used the intravenous equivalent, aminophylline
(Peliowski 1990) or theophylline (Sims 1985). Two trials exam-
ined the effects of caffeine (Murat 1981; Erenberg 2000).
All trials measured apnea/bradycardia consistent with clinical
events as defined inBackground (AAP 2003). These were recorded
from clinical monitors in two trials (Gupta 1981; Erenberg 2000)
and by chart records of apnea and heart rate in the remaining
three. The timing of outcome assessments varied from 48 hrs to
10 days after initiation of treatment.
In the Erenberg 2000 trial, a large number of infants exited from
double blind treatment during the 10 day study period and failure
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was determined on the day of exit and “carried forward over the
subsequent days” (the status on day seven when responses were
stable was taken for the result presented here).
A new trial (CAP Trial 2006) comparing outcomes at discharge
and infant follow-up of caffeine versus placebo is awaiting assess-
ment. It cannot be included in this review yet, because despite
one indication for inclusion of participants being appropriate (caf-
feine treatment of apnea of prematurity), two other indications
for inclusion in the trial and published results were prophylactic
methylxanthine for apnea of prematurity or prophylactic methylx-
anthines for extubation in preterm infants. The latter are poten-
tially eligible for two other Cochrane reviews (Henderson-Smart
2006, Henderson-Smart 2006a).
Risk of bias in included studies
Details of each study appear in the table of included studies. There
was variation in trial design. Peliowski 1990 clearly concealed ran-
domization and used placebo controls; Erenberg 2000 used an un-
clear method of randomization and placebo controls; Gupta 1981
used a quasi-random method with placebo controls; Sims 1985
and Murat 1981 used an unspecified method of randomization
without placebo blinding.
Effects of interventions
Compared with control (placebo or no drug therapy), methylxan-
thine administration to infants with recurrent apnea of prematu-
rity is followed by less treatment failure [summary RR 0.43 (0.31,
0.60), RD -0.40 (-0.53, -0.28), NNT 3 (2, 4)] and less use of
IPPV [RR 0.34 (0.12, 0.97), RD -0.08 (-0.16, -0.01), NNT 13
(6, 100)]. These effect sizes are large although the sample sizes are
low.
These effects were analysed in the short-term only, with two of the
studies (Gupta 1981; Peliowski 1990) evaluating effects 48 hours
after randomizations, another study at five days (Murat 1981), and
the other two studies (Sims 1985; Erenberg 2000) at one week.
Although Sims 1985 claimed that there were no benefits by seven
days, the mean number of apneic events was analysed only in the
subgroup that did not require mechanical ventilation.
The results were similar across trials. Analysis of the three tri-
als in which theophylline was used also showed significantly less
treatment failure [summary RR 0.41 (0.27, 0.62), RD -0.50 (-
0.67, -0.33), NNT 2 (1, 3)] and a reduction in use of IPPV that
nearly reaches statistical significance. The two trials (Murat 1981;
Erenberg 2000) evaluating caffeine, found significantly less treat-
ment failure [summary RR 0.46 (0.27, 0.78), RD -0.31 (-0.49, -
0.12), NNT 3 (2, 8)].
The difference in the low rate of death before discharge (methylx-
anthine 3/81 versus control 6/73) reported in three trials (Gupta
1981, Sims 1985, Erenberg 2000) is not significant.
Side effects were reported in three trials. Two reported that there
were none (Peliowski 1990; Sims 1985) andone trial (Gupta 1981)
reported that two infants in the theophylline group developed
tachycardia. Erenberg 2000 provided the additional information
that no infants had side effects such as tachycardia or feed intol-
erance leading to omission of treatment.
Long-term effects on growth and neurodevelopment were not as-
sessed in any included trials.
D I S C U S S I O N
Although avoiding the use of IPPV seems an appropriate clini-
cal goal, it is not clear whether merely reducing the number of
apneic episodes alters the long term outcome. Older small co-
hort studies have not been able to detect any independent ad-
verse effect of apnea on later neurological development (reviewed
by Henderson-Smart 2004; Comer 2001). A recent large cohort
study (Davis 2000) raises concerns that there could be increased
rates of cerebral palsy associated with caffeine use even after adjust-
ment for confounders. This study also suggests that infants treated
with caffeine, again after adjusting for confounders, might have a
higher full scale and verbal intelligence quotients as measured by
the Wechsler Intelligence Scale (WISC III) for children.
Data here and in another systematic review comparing caffeine
and theophylline (Steer 2004) suggest that the short-term benefits
of caffeine are similar to those of theophylline. Side effects appear
to be less common with caffeine (reviewed by Blanchard 1992;
Steer 2004; Comer 2001).
Although methylxanthines lead to a reduction of apnea in preterm
infants who have this clinical problem, they are not effective when
given as prophylaxis to spontaneously breathing preterm infants
at risk of developing apnea/bradycardia because of their low ges-
tational age (Henderson-Smart 2006a). Another review indicates
that methylxanthines may be effective in facilitating extubation
from IPPV in some infants and that this is partly due to a reduc-
tion in postextubation apnea (Henderson-Smart 2006).
The incidence as well as the severity of the clinical apnea is greatest
in infants born at earlier gestational ages. It might be expected
that infants born at the lowest gestation would benefit most from
treatment. No study evaluated this as part of the initial stated
aim so this prespecified subgroup analysis could not be done. In
one study (Sims 1985), post-hoc analysis showed that 8 of the 11
control infants who required mechanical ventilation were born at
less than 31 weeks gestation.
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A major concern is the small numbers in each study which, while
adequate to show the large effect on apnea, would not be able to
detect less common adverse effects. Of particularly concern is the
lack of trial data on long-term growth and development. The CAP
Trial (CAP Trial 2006) has published outcomes at discharge and
growth and development at 18 to 21months. These results include
a large number of very low birthweight infants (Caffeine group
1006, placebo group 1000) with any one of the three indications
for trial entry (prophylaxis prevention of apnea in 22%, treatment
of apnea in 40% or prophylaxis for extubation in 38%). At present
the results cannot be specifically applied to this reviewon treatment
for apnea, although they do provide a generalised effect of caffeine
indicating that there is improved outcome at discharge and in
neurodevelopment at follow-up. The CAP trial authors have been
requested to evaluate outcomes for each indication which will
make the trial eligible for inclusion in this review and also the
other twoCochrane reviews dealingwith the other two indications
(Henderson-Smart 2006a; Henderson-Smart 2006) and allow for
a more precise understanding of the effects in these related but
different populations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Methylxanthines are effective in reducing the number of apneic
attacks in the short-term and in reducing the use of mechanical
ventilation. In view of its lower toxicity, caffeine would be the
preferred drug. In included studies, the safety of methylxanthine
therapy is uncertain, especially in terms of lack of long-termgrowth
and neurodevelopment outcomes.
Implications for research
In order to indicate which infants are likely to benefit from treat-
ment, there is a need for stratification by gestation and/or other
risk factors in future studies. In any future studies the longer term
effects of treatment on growth and development should be evalu-
ated. Data on neonatal and longer term outcome might be avail-
able for infants given caffeine treatment for recurrent apnea in the
trial of general caffeine use, awaiting assessment (CAPTrial 2006).
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Erenberg 2000
Methods Blinding of randomization - unclear; blinding of intervention - yes; complete follow up - 5 (6%) infants
withdrawn after randomization (1 caffeine infant and 2 placebo infants did not meet apnea inclusion
criteria during baseline measurement, 2 placebo infants never received drug); blinding of outcome assess-
ment - yes
Participants Multicentre (9); 87 preterm infants 28 - 32 weeks postmenstrual age and less than 24 hrs of age with six
or more apnea episodes (> 20 secs duration) in 24 hrs. Exclusions: secondary apnea (CNS, lung disease,
anemia, infection, shock)
Interventions Caffeine citrate (10 mg/kg base) IV and 2.5 mg/kg daily vs placebo (citric acid/sodium citrate)
Outcomes Failure = < 50% reduction in apnea (> 20 secs); use of IPPV (provided by author); death by 30 days
Notes Clinical observations of monitors used to assess outcome. Use of open label caffeine allowed at discretion
of staff (14 caffeine and 16 placebo), also 10 caffeine and 9 placebo infants withdrawn from double blind
treatment (adverse event 2 vs 1, apnea recurrence 5 vs 6, investigator discretion 2 vs 2, transferred 1 vs
0. 21 caffeine and 12 placebo infants completed full 10 days of double blind treatment. Author provided
information that no infant received IPPV or had side effects such as tachycardia leading to withholding
treatment
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Gupta 1981
Methods Blinding of randomization - unclear (pharmacymade up 4mixtures labelled a,b,c,d,e,f; letter drawn from a
’hat’); blinding of treatment - yes; completeness of follow-up - no (3 subjects excluded after randomisation)
; blinding of outcome assessment - yes
Participants 29 preterm infants born at 26 to 34 weeks gestation who had clinical apnea; >3 events per 12 hours of
apnea >15 sec with heart rate < 100 or cyanosis; infants in treatment and placebo groups were of similar
mean gestational age (28.6 vs 29.1 weeks) and mean birth weight (1101 vs 1171 gms); commenced on
treatment at median of 7 (range 2-19) days and placebo at median of 8.5 (range 1-29) days
Interventions Oral theophylline (4 mg/kg 6 hourly, increased to 6 mg/kg if no response to first dose) vs placebo
Outcomes Apnea (no decrease in first 6-12 hours or need for nursing interventions for events in the next 48 hours)
; use of mechanical ventilation (personal communication); death before hospital discharge; tachycardia
leading to an adjustment of dose
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Gupta 1981 (Continued)
Notes Dose of theophylline high but no loading dose given. Clinical observations of monitors used to detect
apnea/bradycardia. No power calculation given; trial terminated early
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Murat 1981
Methods Blinding of randomization - unclear; blinding of intervention - no; complete followup - yes; blinding of
outcome measurement - no
Participants 18 preterm infants with apnea (>2 apneas with heart rate <100 per day); treatment and untreated controls
of similar mean gestational age (30.1 vs 29.8 weeks) , birth weight (1247 vs 1411 gms) , postnatal age at
study entry (13.2 vs 16.1 days) and frequency of apnea in the day before study entry (1.17 vs 0.65 /100
mins)
Interventions Caffeine sodium citrate (20 mg/kg load im, then 5 mg/kg/day oral) vs no treatment
Outcomes Failure onday 1 andday 5 (continued apnea or use ofmechanical ventilation); use ofmechanical ventilation
Notes Four infants in the untreated group crossed over during the study and were classified as ’failed treatment’.
Chart recording of apnea/bradycardia used
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Peliowski 1990
Methods Blinding of randomisation - yes; blinding of intervention - yes; complete followup - 3 withdrawals after
randomization (parental request, suspected sepsis, possible seizures) , groups not specified; blinding of
outcome measurement - yes
Participants 20 preterm infants (<35 weeks gestation) with apnea ( apnea > 20 sec with > 25% fall in heart rate and
10% fall in oxygen saturation or 5 torr or more fall in transcutaneous oxygen tension; 0.33 or more events
per hr) ; other causes of apnea excluded; similar mean gestational age (30.7 vs 31.3 weeks), birth weight
(1441 vs 1598 g), postnatal age at study entry (4.0 vs 2.9) and baseline apnea rate (0.72 vs 0.70/hr)
Interventions Theophylline (8 mg/kg load iv then continuous iv infusion of 0.5 mg/kg/hr) vs placebo.
Cross over design (after 48 hrs) and comparison with doxapram - not evaluated here
8Methylxanthine treatment for apnea in preterm infants (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Peliowski 1990 (Continued)
Outcomes Failure [apnea rate not below 0.33/hr (baseline rate 0.70/hr in treatment group and 0.72/hr in controls)
or use of mechanical ventilation by 48 hrs]; use of mechanical ventilation
Notes Three infants withdrawn after randomisation (parental request, suspected sepsis, possible seizures) and
use of continuous positive airways pressure was permitted at the discretion of the clinician (no data given)
- seeking author clarification. Chart recording of apnea/bradycardia used
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Sims 1985
Methods Blinding of randomisation unclear; blinding of intervention - no; complete follow-up - yes; blinding of
outcome measurement - no
Participants 43 preterm (<37 weeks gestation) infants; infants in treatment and no treated groups were of similar mean
gestational age (31.4 vs 30.8 weeks) , mean birth weight (1345 vs 1306 gms) and postnatal age at study
entry (2.5 vs 2.0 days)
Interventions Theophylline (6.8 mg/kg load iv, then 1.4 mg/kg 8 hourly) vs no treatment
Outcomes Failure (no ’resolution’ of apnea or use of mechanical ventilation by 7 days); use of mechanical ventilation;
death before hospital discharge
Notes Used continuous print out on chart recorder to detect apnea and bradycardia
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Hochwald 2002 This trial compared two loading doses of aminophylline without a control group
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D A T A A N D A N A L Y S E S
Comparison 1. Any methylxanthine vs control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failed treatment after 2 - 7 days 5 192 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.32, 0.60]
2 Use of mechanical ventilation 5 192 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.12, 0.97]
3 Side effects 4 149 Risk Ratio (M-H, Fixed, 95% CI) 4.69 [0.24, 89.88]
4 Death before discharge 3 154 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.14, 1.78]
Comparison 2. Theophylline vs control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failed treatment after 2 - 7 days 3 92 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.28, 0.63]
2 Use of mechanical ventilation 3 92 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.13, 1.16]
3 Side effects 2 49 Risk Ratio (M-H, Fixed, 95% CI) 4.69 [0.24, 89.88]
4 Death before discharge 2 72 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.05, 1.52]
Comparison 3. Caffeine vs control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failed treatment after 5 - 7 days 2 100 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.27, 0.78]
2 Use of mechanical ventilation 2 100 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.66]
3 Side effects 2 100 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Death before discharge 1 82 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.16, 17.43]
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Analysis 1.1. Comparison 1 Any methylxanthine vs control, Outcome 1 Failed treatment after 2 - 7 days.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 1 Any methylxanthine vs control
Outcome: 1 Failed treatment after 2 - 7 days
Study or subgroup Methylxanthine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 14/45 20/37 32.3 % 0.58 [ 0.34, 0.97 ]
Gupta 1981 5/15 14/14 22.0 % 0.36 [ 0.18, 0.70 ]
Murat 1981 0/9 6/9 9.6 % 0.08 [ 0.00, 1.19 ]
Peliowski 1990 2/10 8/10 11.8 % 0.25 [ 0.07, 0.90 ]
Sims 1985 9/21 17/22 24.4 % 0.55 [ 0.32, 0.95 ]
Total (95% CI) 100 92 100.0 % 0.44 [ 0.32, 0.60 ]
Total events: 30 (Methylxanthine), 65 (Control)
Heterogeneity: Chi2 = 4.43, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 5.04 (P < 0.00001)
0.005 0.1 1 10 200
Favors methylxan. Favors control
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Analysis 1.2. Comparison 1 Any methylxanthine vs control, Outcome 2 Use of mechanical ventilation.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 1 Any methylxanthine vs control
Outcome: 2 Use of mechanical ventilation
Study or subgroup Methylxanthine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 0/45 0/37 Not estimable
Gupta 1981 0/15 0/14 Not estimable
Murat 1981 0/9 2/9 21.2 % 0.20 [ 0.01, 3.66 ]
Peliowski 1990 0/10 1/10 12.7 % 0.33 [ 0.02, 7.32 ]
Sims 1985 3/21 8/22 66.1 % 0.39 [ 0.12, 1.28 ]
Total (95% CI) 100 92 100.0 % 0.34 [ 0.12, 0.97 ]
Total events: 3 (Methylxanthine), 11 (Control)
Heterogeneity: Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
0.01 0.1 1 10 100
Favors methylxan. Favors control
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Analysis 1.3. Comparison 1 Any methylxanthine vs control, Outcome 3 Side effects.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 1 Any methylxanthine vs control
Outcome: 3 Side effects
Study or subgroup Methylxanthine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 0/45 0/37 Not estimable
Gupta 1981 2/15 0/14 100.0 % 4.69 [ 0.24, 89.88 ]
Murat 1981 0/9 0/9 Not estimable
Peliowski 1990 0/10 0/10 Not estimable
Total (95% CI) 79 70 100.0 % 4.69 [ 0.24, 89.88 ]
Total events: 2 (Methylxanthine), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.31)
0.02 0.1 1 10 50
Favors methylxan. Favours control
Analysis 1.4. Comparison 1 Any methylxanthine vs control, Outcome 4 Death before discharge.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 1 Any methylxanthine vs control
Outcome: 4 Death before discharge
Study or subgroup Methylxanine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 2/45 1/37 16.5 % 1.64 [ 0.16, 17.43 ]
Gupta 1981 1/15 3/14 46.7 % 0.31 [ 0.04, 2.65 ]
Sims 1985 0/21 2/22 36.8 % 0.21 [ 0.01, 4.11 ]
Total (95% CI) 81 73 100.0 % 0.49 [ 0.14, 1.78 ]
Total events: 3 (Methylxanine), 6 (Control)
Heterogeneity: Chi2 = 1.50, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
0.02 0.1 1 10 50
Favors methylxanth. Favors control
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Analysis 2.1. Comparison 2 Theophylline vs control, Outcome 1 Failed treatment after 2 - 7 days.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 2 Theophylline vs control
Outcome: 1 Failed treatment after 2 - 7 days
Study or subgroup Theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gupta 1981 5/15 14/14 37.8 % 0.36 [ 0.18, 0.70 ]
Peliowski 1990 2/10 8/10 20.2 % 0.25 [ 0.07, 0.90 ]
Sims 1985 9/21 17/22 42.0 % 0.55 [ 0.32, 0.95 ]
Total (95% CI) 46 46 100.0 % 0.42 [ 0.28, 0.63 ]
Total events: 16 (Theophylline), 39 (Control)
Heterogeneity: Chi2 = 1.88, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
0.1 0.2 0.5 1 2 5 10
Favors theophylline Favors control
14Methylxanthine treatment for apnea in preterm infants (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Theophylline vs control, Outcome 2 Use of mechanical ventilation.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 2 Theophylline vs control
Outcome: 2 Use of mechanical ventilation
Study or subgroup Theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gupta 1981 0/15 0/14 Not estimable
Peliowski 1990 0/10 1/10 16.1 % 0.33 [ 0.02, 7.32 ]
Sims 1985 3/21 8/22 83.9 % 0.39 [ 0.12, 1.28 ]
Total (95% CI) 46 46 100.0 % 0.38 [ 0.13, 1.16 ]
Total events: 3 (Theophylline), 9 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
0.02 0.1 1 10 50
Favors theopylline Favors control
Analysis 2.3. Comparison 2 Theophylline vs control, Outcome 3 Side effects.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 2 Theophylline vs control
Outcome: 3 Side effects
Study or subgroup Theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gupta 1981 2/15 0/14 100.0 % 4.69 [ 0.24, 89.88 ]
Peliowski 1990 0/10 0/10 Not estimable
Total (95% CI) 25 24 100.0 % 4.69 [ 0.24, 89.88 ]
Total events: 2 (Theophylline), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.31)
0.02 0.1 1 10 50
Favors theophylline Favors control
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Analysis 2.4. Comparison 2 Theophylline vs control, Outcome 4 Death before discharge.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 2 Theophylline vs control
Outcome: 4 Death before discharge
Study or subgroup Theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gupta 1981 1/15 3/14 55.9 % 0.31 [ 0.04, 2.65 ]
Sims 1985 0/21 2/22 44.1 % 0.21 [ 0.01, 4.11 ]
Total (95% CI) 36 36 100.0 % 0.27 [ 0.05, 1.52 ]
Total events: 1 (Theophylline), 5 (Control)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
0.01 0.1 1 10 100
Favors theophylline Favors control
Analysis 3.1. Comparison 3 Caffeine vs control, Outcome 1 Failed treatment after 5 - 7 days.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 3 Caffeine vs control
Outcome: 1 Failed treatment after 5 - 7 days
Study or subgroup Caffeine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 14/45 20/37 77.2 % 0.58 [ 0.34, 0.97 ]
Murat 1981 0/9 6/9 22.8 % 0.08 [ 0.00, 1.19 ]
Total (95% CI) 54 46 100.0 % 0.46 [ 0.27, 0.78 ]
Total events: 14 (Caffeine), 26 (Control)
Heterogeneity: Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 2.91 (P = 0.0036)
0.005 0.1 1 10 200
Favors caffeine Favors control
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Analysis 3.2. Comparison 3 Caffeine vs control, Outcome 2 Use of mechanical ventilation.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 3 Caffeine vs control
Outcome: 2 Use of mechanical ventilation
Study or subgroup Caffeine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 0/45 0/37 Not estimable
Murat 1981 0/9 2/9 100.0 % 0.20 [ 0.01, 3.66 ]
Total (95% CI) 54 46 100.0 % 0.20 [ 0.01, 3.66 ]
Total events: 0 (Caffeine), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.02 0.1 1 10 50
Favors caffeine Favors control
Analysis 3.3. Comparison 3 Caffeine vs control, Outcome 3 Side effects.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 3 Caffeine vs control
Outcome: 3 Side effects
Study or subgroup Caffeine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 0/45 0/37 Not estimable
Murat 1981 0/9 0/9 Not estimable
Total (95% CI) 54 46 Not estimable
Total events: 0 (Caffeine), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favors caffeine Favors control
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Analysis 3.4. Comparison 3 Caffeine vs control, Outcome 4 Death before discharge.
Review: Methylxanthine treatment for apnea in preterm infants
Comparison: 3 Caffeine vs control
Outcome: 4 Death before discharge
Study or subgroup Caffeine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erenberg 2000 2/45 1/37 100.0 % 1.64 [ 0.16, 17.43 ]
Total (95% CI) 45 37 100.0 % 1.64 [ 0.16, 17.43 ]
Total events: 2 (Caffeine), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
0.1 0.2 0.5 1 2 5 10
Favors caffeine Favors control
WH A T ’ S N E W
Last assessed as up-to-date: 5 February 2008.
Date Event Description
12 August 2009 Amended Corrections made to citations in ’Studies awaiting classification’
H I S T O R Y
Protocol first published: Issue 4, 1999
Review first published: Issue 4, 1999
Date Event Description
6 February 2008 Amended Converted to new review format.
6 February 2008 New search has been performed This reviewupdates the existing review of ’Methylxanthine treatment for apnea
in preterm infants’ which was published in The Cochrane Library, Issue 4,
2004 (Henderson-Smart 2004).
One new trial has been published, but requires further analysis of the data.
This trial is referenced in ’Studies awaiting classification”. The conclusions of
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(Continued)
this review are unchanged
C O N T R I B U T I O N S O F A U T H O R S
Both review authors developed the protocol, evaluated trials and extracted data.
Henderson-Smart wrote the review and entered the data into RevMan.
Henderson-Smart has been responsible for searching for trials and updating the review with the approval of Steer.
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None
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• NSW Centre for Perinatal Health Services Research, University of Sydney, Australia.
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use]; Xanthines [∗therapeutic use]
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